Sanofi has paid $45m via an upfront licensing fee and equity investment in young South San Francisco-based biotech MyoKardia, which is developing targeted therapies for genetic heart disease. The collaboration is an outgrowth of Sanofi's Sunrise initiative, a partnership model focused on early stage opportunities.
MyoKardia was formed in 2012 with a £38m series A financing from Third Rock Ventures (scripintelligence.com, 24 September 2012)
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?